Catalent Inc (NYSE:CTLT) – Analysts at William Blair dropped their FY2020 earnings estimates for shares of Catalent in a report issued on Monday, April 15th. William Blair analyst J. Kreger now expects that the company will post earnings per share of $1.69 for the year, down from their previous forecast of $1.84.
A number of other brokerages have also commented on CTLT. Morgan Stanley boosted their price target on shares of Catalent from $46.00 to $50.00 and gave the company an “overweight” rating in a research note on Tuesday. First Analysis restated an “outperform” rating and set a $49.00 price target on shares of Catalent in a research note on Tuesday, March 5th. Zacks Investment Research upgraded shares of Catalent from a “hold” rating to a “buy” rating and set a $44.00 price target for the company in a research note on Wednesday, February 6th. TheStreet upgraded shares of Catalent from a “c” rating to a “b-” rating in a research note on Wednesday, February 6th. Finally, ValuEngine lowered shares of Catalent from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Catalent presently has an average rating of “Buy” and a consensus target price of $49.57.
Catalent (NYSE:CTLT) last released its quarterly earnings data on Tuesday, February 5th. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.08. The company had revenue of $623.00 million during the quarter, compared to analyst estimates of $608.38 million. Catalent had a net margin of 5.48% and a return on equity of 17.42%. Catalent’s revenue for the quarter was up 2.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.45 EPS.
Large investors have recently modified their holdings of the stock. Sageworth Trust Co purchased a new position in shares of Catalent in the 1st quarter worth about $32,000. Quantamental Technologies LLC purchased a new position in shares of Catalent in the 4th quarter worth about $47,000. Bremer Trust National Association purchased a new position in shares of Catalent in the 4th quarter worth about $54,000. Enlightenment Research LLC purchased a new position in shares of Catalent in the 4th quarter worth about $56,000. Finally, Oregon Public Employees Retirement Fund boosted its holdings in shares of Catalent by 3,074.3% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 1,798,868 shares of the company’s stock worth $58,000 after buying an additional 1,742,199 shares during the last quarter. 99.82% of the stock is currently owned by institutional investors.
In related news, insider Aristippos Gennadios sold 3,392 shares of the business’s stock in a transaction dated Thursday, March 21st. The shares were sold at an average price of $42.18, for a total value of $143,074.56. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Lance Miyamoto sold 43,619 shares of the business’s stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $42.49, for a total transaction of $1,853,371.31. The disclosure for this sale can be found here. In the last quarter, insiders sold 54,326 shares of company stock valued at $2,303,676. Company insiders own 1.40% of the company’s stock.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.